Rasburicase
- Generic Name
- Rasburicase
- Brand Names
- Elitek, Fasturtec
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 134774-45-1
- Unique Ingredient Identifier
- 08GY9K1EUO
- Background
Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
- Indication
For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
- Associated Conditions
- Hyperuricemia
- Associated Therapies
- -
Rasburicase Treatment in Chronic Gouty Arthritis
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2023-05-09
- Target Recruit Count
- 60
- Registration Number
- NCT05312268
- Locations
- 🇨🇳
Shenshan Medical Center, Shanwei, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Shunde Hospital of Southern Medical University, Foshan, Guangdong, China
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04745910
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Uric Acid Effects on Endothelium and Oxydative Stress
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Erasme University Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT03395977
- Locations
- 🇧🇪
Erasme Hospital, Brussels, Belgique, Belgium
Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 31
- Registration Number
- NCT01931527
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
- Conditions
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaContiguous Stage II Adult Burkitt Lymphomade Novo Myelodysplastic SyndromesRecurrent Adult Burkitt LymphomaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesPreviously Treated Myelodysplastic SyndromesStage III Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2012-03-27
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT01564277
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT01200485
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lowering Serum Uric Acid to Prevent Acute Kidney Injury
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 26
- Registration Number
- NCT00756964
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Fasturtec TLS Treatment / Prophylysis
- Conditions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT00651911
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Rasburicase (Fasturtec) Registration Trial
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT00607152
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
- Conditions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT00563771
- Locations
- 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.